Literature DB >> 6289314

Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.

S C Rall, K H Weisgraber, T L Innerarity, R W Mahley.   

Abstract

The three major isoforms of human apolipoprotein E (apo-E2, -E3, and -E4) are coded for by three alleles (epsilon 2, epsilon 3, and epsilon 4) which have a common genetic locus. Previously, we demonstrated that E2, E3, and E4 differ in primary structure from one another at two substitution sites, site A (residue 112) and site B (residue 158). At sites A/B, apo-E2, -E3, and -E4 contain cysteine/cysteine, cysteine/arginine, and arginine/arginine, respectively. We demonstrated that the substitution of cysteine for arginine at site B is at least partly responsible for the defective binding of apo-E2 to human fibroblast low density lipoprotein receptors, compared to the normal binding activity of apo-E3 or -E4. Subjects with the genetic disorder type III hyperlipoproteinemia are phenotypically homozygous for apo-E2, but the binding activity of apo-E to the fibroblast receptor differs considerably from one type III individual to another. We therefore undertook a partial comparative sequence analysis of apo-E2 from three type III subjects whose apo-E displayed this heterogeneity. The subject with the poorest binding apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cysteine was found at sites A and B. The subject with the most active apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cystine was found at site A and at a new site (site C, residue 145). The epsilon 2 allele specifies a protein that has arginine at site B (residue 158); the epsilon 2 allele specifies a protein that has arginine at site C (residue 145). Therefore, the two alleles differ from one another by cysteine/arginine interchanges at two positions, sites B and C. The third subject, whose apo-E2 displayed binding activity intermediate between the activities of the other two, was genotypically heterozygous, having one epsilon 2 allele and one epsilon 2 allele. The intermediate binding activity of apo-E2 from this subject resulted from having a mixture of severely defective apo-E (specified by epsilon 2) and slightly defective apo-E (specified by epsilon 2).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289314      PMCID: PMC346743          DOI: 10.1073/pnas.79.15.4696

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts.

Authors:  T L Innerarity; R E Pitas; R W Mahley
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

2.  Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins.

Authors:  G Utermann; M Jaeschke; J Menzel
Journal:  FEBS Lett       Date:  1975-08-15       Impact factor: 4.124

3.  Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins.

Authors:  T L Innerarity; R W Mahley
Journal:  Biochemistry       Date:  1978-04-18       Impact factor: 3.162

4.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

5.  Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification.

Authors:  V I Zannis; J L Breslow
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

6.  Characterization of a unique human apolipoprotein E variant associated with type III hyperlipoproteinemia.

Authors:  V I Zannis; J L Breslow
Journal:  J Biol Chem       Date:  1980-03-10       Impact factor: 5.157

7.  Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process.

Authors:  B C Sherrill; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1980-03-10       Impact factor: 5.157

8.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia.

Authors:  A Pagnan; R J Havel; J P Kane; L Kotite
Journal:  J Lipid Res       Date:  1977-09       Impact factor: 5.922

9.  Human apolipoprotein E isoprotein subclasses are genetically determined.

Authors:  V I Zannis; P W Just; J L Breslow
Journal:  Am J Hum Genet       Date:  1981-01       Impact factor: 11.025

10.  Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia.

Authors:  R J Havel; Y Chao; E E Windler; L Kotite; L S Guo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

View more
  70 in total

1.  LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.

Authors:  Alexina Orsoni; Samir Saheb; Johannes H M Levels; Geesje Dallinga-Thie; Marielle Atassi; Randa Bittar; Paul Robillard; Eric Bruckert; Anatol Kontush; Alain Carrié; M John Chapman
Journal:  J Lipid Res       Date:  2011-09-26       Impact factor: 5.922

Review 2.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Profile of Robert W. Mahley.

Authors:  Regina Nuzzo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

4.  High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).

Authors:  D A Chappell
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

5.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

6.  A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.

Authors:  K H Weisgraber; S C Rall; T L Innerarity; R W Mahley; T Kuusi; C Ehnholm
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis.

Authors:  Carmel M Quinn; Katarina Kågedal; Alexei Terman; Uri Stroikin; Ulf T Brunk; Wendy Jessup; Brett Garner
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

8.  Apolipoprotein-E forms dimers in human frontal cortex and hippocampus.

Authors:  David A Elliott; Glenda M Halliday; Brett Garner
Journal:  BMC Neurosci       Date:  2010-02-20       Impact factor: 3.288

9.  Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.

Authors:  A F Stalenhoef; M J Malloy; J P Kane; R J Havel
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

10.  Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations.

Authors:  Maen D Abou Ziki; Yael Strulovici-Barel; Neil R Hackett; Juan L Rodriguez-Flores; Jason G Mezey; Jacqueline Salit; Sharon Radisch; Charleen Hollmann; Lotfi Chouchane; Joel Malek; Mahmoud A Zirie; Amin Jayyuosi; Antonio M Gotto; Ronald G Crystal
Journal:  Am J Cardiol       Date:  2013-10-03       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.